Michael Joseph Rybak
#113,323
Most Influential Person Now
Researcher
Michael Joseph Rybak's AcademicInfluence.com Rankings
Michael Joseph Rybakengineering Degrees
Engineering
#3350
World Rank
#4414
Historical Rank
Electrical Engineering
#735
World Rank
#799
Historical Rank
Michael Joseph Rybakcomputer-science Degrees
Computer Science
#4351
World Rank
#4581
Historical Rank
Computational Linguistics
#397
World Rank
#403
Historical Rank
Machine Learning
#824
World Rank
#835
Historical Rank
Artificial Intelligence
#1033
World Rank
#1051
Historical Rank
Download Badge
Engineering Computer Science
Michael Joseph Rybak's Degrees
- PhD Computer Science Stanford University
- Masters Electrical Engineering University of California, Berkeley
Similar Degrees You Can Earn
Why Is Michael Joseph Rybak Influential?
(Suggest an Edit or Addition)Michael Joseph Rybak's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association (2015) (1907)
- Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. (2009) (746)
- The pharmacokinetic and pharmacodynamic properties of vancomycin. (2006) (643)
- Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteremia. (2003) (584)
- Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Socie (2020) (566)
- Prospective Evaluation of the Effect of an Aminoglycoside Dosing Regimen on Rates of Observed Nephrotoxicity and Ototoxicity (1999) (395)
- Nephrotoxicity of vancomycin, alone and with an aminoglycoside. (1990) (370)
- Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. (2011) (368)
- Therapeutic Monitoring of Vancomycin in Adults (2009) (359)
- In Vitro Activities of Daptomycin, Vancomycin, Linezolid, and Quinupristin-Dalfopristin against Staphylococci and Enterococci, Including Vancomycin- Intermediate and -Resistant Strains (2000) (341)
- Impact of High-Inoculum Staphylococcus aureus on the Activities of Nafcillin, Vancomycin, Linezolid, and Daptomycin, Alone and in Combination with Gentamicin, in an In Vitro Pharmacodynamic Model (2004) (296)
- Pharmacodynamics of cefepime in patients with Gram-negative infections. (2002) (225)
- The importance of bactericidal drugs: future directions in infectious disease. (2004) (210)
- Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V (2001) (182)
- Tigecycline: First of a New Class of Antimicrobial Agents (2006) (177)
- Ceragenins: cholic acid-based mimics of antimicrobial peptides. (2008) (171)
- Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: a matched cohort study. (2013) (169)
- Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections (1996) (168)
- A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity (2017) (152)
- Community‐Associated Methicillin‐Resistant Staphylococcus aureus: A Review (2005) (150)
- Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections (1996) (150)
- Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline. (2014) (147)
- Comparative In Vitro Activities and Postantibiotic Effects of the Oxazolidinone Compounds Eperezolid (PNU-100592) and Linezolid (PNU-100766) versus Vancomycin against Staphylococcus aureus, Coagulase-Negative Staphylococci, Enterococcus faecalis, and Enterococcus faecium (1998) (146)
- The Pharmacologic and Bacteriologic Properties of Oxazolidinones, a New Class of Synthetic Antimicrobials (1998) (144)
- Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) (2008) (144)
- The β‐Lactams Strike Back: Ceftazidime‐Avibactam (2015) (142)
- Comparison of Length of Hospital Stay for Patients with Known or Suspected Methicillin‐Resistant Staphylococcus Species Infections Treated with Linezolid or Vancomycin: A Randomized, Multicenter Trial (2001) (136)
- Risk of Acute Kidney Injury in Patients on Concomitant Vancomycin and Piperacillin–Tazobactam Compared to Those on Vancomycin and Cefepime (2017) (135)
- High‐Dose Daptomycin for Treatment of Complicated Gram‐Positive Infections: A Large, Multicenter, Retrospective Study (2011) (134)
- Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006 (2009) (132)
- Vancomycin pharmacokinetics in burn patients and intravenous drug abusers (1990) (127)
- Effects of NorA Inhibitors on In Vitro Antibacterial Activities and Postantibiotic Effects of Levofloxacin, Ciprofloxacin, and Norfloxacin in Genetically Related Strains ofStaphylococcus aureus (1999) (127)
- Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. (2006) (126)
- In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin (1992) (126)
- Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance. (2009) (124)
- Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa (1996) (123)
- Pharmacodynamics: relation to antimicrobial resistance. (2006) (122)
- Activities of High-Dose Daptomycin, Vancomycin, and Moxifloxacin Alone or in Combination with Clarithromycin or Rifampin in a Novel In Vitro Model of Staphylococcus aureus Biofilm (2010) (121)
- Short-Course Gentamicin in Combination with Daptomycin or Vancomycin against Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations (2005) (120)
- Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model (2012) (120)
- A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis (2018) (119)
- Clinical outcomes for patients with bacteremia caused by vancomycin-resistant enterococcus in a level 1 trauma center. (2002) (112)
- Impact of Empirical-Therapy Selection on Outcomes of Intravenous Drug Users with Infective Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus (2007) (111)
- The Triazole Antifungal Agents: A Review of Itraconazole and Fluconazole (1990) (111)
- Validated Risk Score for Predicting 6‐Month Mortality in Infective Endocarditis (2016) (108)
- Community- and health care-associated methicillin-resistant Staphylococcus aureus: a comparison of molecular epidemiology and antimicrobial activities of various agents. (2007) (106)
- Characteristics of Patients With Healthcare-Associated Infection Due to SCCmec Type IV Methicillin-Resistant Staphylococcus aureus (2006) (105)
- Pharmacokinetics and Pharmacodynamics of Cefepime in Patients with Various Degrees of Renal Function (2003) (103)
- Evaluation of Daptomycin Pharmacodynamics and Resistance at Various Dosage Regimens against Staphylococcus aureus Isolates with Reduced Susceptibilities to Daptomycin in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations (2008) (103)
- Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin (2017) (102)
- Validation of the Effectiveness of a Vancomycin Nomogram in Achieving Target Trough Concentrations of 15–20 mg/L Suggested by the Vancomycin Consensus Guidelines (2011) (101)
- A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis. (2013) (100)
- Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. (2005) (99)
- Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations (2012) (98)
- Activities of Clindamycin, Daptomycin, Doxycycline, Linezolid, Trimethoprim-Sulfamethoxazole, and Vancomycin against Community-Associated Methicillin-Resistant Staphylococcus aureus with Inducible Clindamycin Resistance in Murine Thigh Infection and In Vitro Pharmacodynamic Models (2008) (98)
- Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms (2003) (96)
- Antimicrobial Activities of Ceragenins against Clinical Isolates of Resistant Staphylococcus aureus (2007) (95)
- β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium. (2015) (94)
- Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy (2014) (92)
- Influences of Linezolid, Penicillin, and Clindamycin, Alone and in Combination, on Streptococcal Pyrogenic Exotoxin A Release (2003) (92)
- Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosa. (2007) (92)
- The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram-positive bacteria. (2006) (92)
- Time Is of the Essence: The Impact of Delayed Antibiotic Therapy on Patient Outcomes in Hospital-Onset Enterococcal Bloodstream Infections. (2016) (92)
- Daptomycin versus Vancomycin for Complicated Skin and Skin Structure Infections: Clinical and Economic Outcomes (2007) (91)
- Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia (1992) (89)
- Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. (2013) (89)
- Acute bacterial skin and skin structure infections (ABSSSI): practice guidelines for management and care transitions in the emergency department and hospital. (2015) (88)
- Antimicrobial susceptibility of Streptococcus pneumoniae, Streptococcus pyogenes and Haemophilus influenzae collected from patients across the USA, in 2001-2002, as part of the PROTEKT US study. (2004) (88)
- Daptomycin Activity against Staphylococcus aureus following Vancomycin Exposure in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations (2007) (87)
- Evaluation of Accessory Gene Regulator (agr) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureus (2006) (86)
- Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections (2013) (85)
- Effects of Targeting Higher Vancomycin Trough Levels on Clinical Outcomes and Costs in a Matched Patient Cohort (2012) (85)
- Pharmacodynamic Characterization of Nephrotoxicity Associated with Once‐Daily Aminoglycoside (1999) (84)
- Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. (2003) (84)
- Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. (2007) (83)
- Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin (1991) (83)
- Evaluation of the Etest GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides. (2009) (83)
- Evaluation of Vancomycin Susceptibility Testing for Methicillin-Resistant Staphylococcus aureus: Comparison of Etest and Three Automated Testing Methods (2013) (83)
- In Vitro Activities of Quinupristin-Dalfopristin and Cefepime, Alone and in Combination with Various Antimicrobials, against Multidrug-Resistant Staphylococci and Enterococci in an In Vitro Pharmacodynamic Model (2002) (83)
- Pharmacodynamics of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with rifampin, against methicillin-susceptible and -resistant Staphylococcus aureus in an in vitro infection model (1994) (79)
- Outcome Assessment of Minimizing Vancomycin Monitoring and Dosing Adjustments (1999) (79)
- Associations between the Genotypes of Staphylococcus aureus Bloodstream Isolates and Clinical Characteristics and Outcomes of Bacteremic Patients (2008) (79)
- Prediction Model to Identify Patients With Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance (2003) (77)
- In Vitro Activity of Ceftaroline against Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate S. aureus in a Hollow Fiber Model (2009) (76)
- Characterization of Vancomycin-Heteroresistant Staphylococcus aureus from the Metropolitan Area of Detroit, Michigan, over a 22-Year Period (1986 to 2007) (2008) (75)
- Inhibition of Drug Metabolism by Quinolone Antibiotics (1988) (75)
- Design, synthesis, and structure-activity relationships of benzophenone-based tetraamides as novel antibacterial agents. (2009) (75)
- In Vitro Activities of Daptomycin, Arbekacin, Vancomycin, and Gentamicin Alone and/or in Combination against Glycopeptide Intermediate-Resistant Staphylococcus aureus in an Infection Model (2000) (74)
- Bactericidal Activities of Daptomycin, Quinupristin-Dalfopristin, and Linezolid against Vancomycin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Model with Simulated Endocardial Vegetations (2003) (73)
- Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. (2003) (73)
- Combination Antimicrobial Therapy for Bacterial Infections (1996) (71)
- Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection (2013) (71)
- Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium. (2002) (70)
- Epidemiology, Resistance, and Outcomes of Acinetobacter baumannii Bacteremia Treated with Imipenem‐Cilastatin or Ampicillin‐Sulbactam (2001) (70)
- Daptomycin – a novel antibiotic against Gram-positive pathogens (2004) (70)
- Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa (2019) (69)
- Efficacy of Triclosan as an Antimicrobial Hand Soap and Its Potential Impact on Antimicrobial Resistance: A Focused Review (2015) (69)
- Dalbavancin: A Novel Lipoglycopeptide Antibiotic with Extended Activity Against Gram-Positive Infections (2015) (69)
- Role of Combination Antimicrobial Therapy for Vancomycin‐Resistant Enterococcus faecium Infections: Review of the Current Evidence (2017) (68)
- Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis (1989) (67)
- Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model (1995) (67)
- Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections (2016) (65)
- Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis (1990) (65)
- Activities of Mutant Prevention Concentration-Targeted Moxifloxacin and Levofloxacin against Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model (2003) (63)
- Association between Vancomycin Day 1 Exposure Profile and Outcomes among Patients with Methicillin-Resistant Staphylococcus aureus Infective Endocarditis (2015) (63)
- Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid. (2016) (63)
- A Pharmacist‐Initiated Program of Intravenous to Oral Antibiotic Conversion (1997) (63)
- Enterococcus, an Emerging Pathogen (1993) (62)
- In Vitro Activity of Ceftaroline Alone and in Combination against Clinical Isolates of Resistant Gram-Negative Pathogens, Including β-Lactamase-Producing Enterobacteriaceae and Pseudomonas aeruginosa (2009) (62)
- Adherence to the 2009 Consensus Guidelines for Vancomycin Dosing and Monitoring Practices: A Cross‐Sectional Survey of U.S. Hospitals (2013) (62)
- Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium (1997) (61)
- Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties (2018) (61)
- Novel Daptomycin Combinations against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations (2010) (61)
- Occurrence of vancomycin-tolerant and heterogeneous vancomycin-intermediate strains (hVISA) among Staphylococcus aureus causing bloodstream infections in nine USA hospitals. (2009) (61)
- Making the change to area under the curve–based vancomycin dosing (2018) (60)
- Bactericidal activities of teicoplanin, vancomycin, and gentamicin alone and in combination against Staphylococcus aureus in an in vitro pharmacodynamic model of endocarditis (1994) (59)
- Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections (2019) (58)
- Novel Combinations of Vancomycin plus Ceftaroline or Oxacillin against Methicillin-Resistant Vancomycin-Intermediate Staphylococcus aureus (VISA) and Heterogeneous VISA (2013) (57)
- Evaluation of Ceftaroline Activity against Heteroresistant Vancomycin-Intermediate Staphylococcus aureus and Vancomycin-Intermediate Methicillin-Resistant S. aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model: Exploring the “Seesaw Effect” (2013) (57)
- Observation of “Seesaw Effect” with Vancomycin, Teicoplanin, Daptomycin and Ceftaroline in 150 Unique MRSA Strains (2014) (57)
- Meropenem and Vaborbactam: Stepping up the Battle against Carbapenem‐resistant Enterobacteriaceae (2018) (56)
- Emergence of Methicillin-Resistant Staphylococcus aureus with Intermediate Glycopeptide Resistance (2012) (56)
- Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. (2003) (56)
- Resistance to Antimicrobial Agents: An Update (2004) (55)
- Teicoplanin pharmacokinetics in intravenous drug abusers being treated for bacterial endocarditis (1991) (55)
- Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the "seesaw effect": Taking advantage of the back door left open? (2013) (55)
- Considerations for the Use of Phage Therapy in Clinical Practice (2022) (55)
- Efficacy of LY333328 against Experimental Methicillin-Resistant Staphylococcus aureus Endocarditis (1998) (55)
- Ceftaroline: A New Cephalosporin with Activity Against Resistant Gram‐Positive Pathogens (2010) (54)
- Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and beta-lactamase-producing strains of Enterobacter aerogenes and Klebsiella pneumoniae in an in vitro infection model (1995) (54)
- Activities of Ceftobiprole, Linezolid, Vancomycin, and Daptomycin against Community-Associated and Hospital-Associated Methicillin-Resistant Staphylococcus aureus (2008) (54)
- Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model (1997) (53)
- In vitro activities of mutant prevention concentration-targeted concentrations of fluoroquinolones against Staphylococcus aureus in a pharmacodynamic model. (2004) (52)
- Multicenter Observational Study of Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (2016) (52)
- Comparison of the Clinical Characteristics and Outcomes Associated with Vancomycin-Resistant Enterococcus faecalis and Vancomycin-Resistant E. faecium Bacteremia (2012) (52)
- Defining Daptomycin Resistance Prevention Exposures in Vancomycin-Resistant Enterococcus faecium and E. faecalis (2014) (51)
- Influence of protein binding under controlled conditions on the bactericidal activity of daptomycin in an in vitro pharmacodynamic model. (2004) (50)
- Evaluation of Acinetobacter baumannii Infection and Colonization, and Antimicrobial Treatment Patterns in an Urban Teaching Hospital (1999) (50)
- Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. (2006) (50)
- Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (2016) (50)
- Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model. (2014) (50)
- Piperazinyl-linked fluoroquinolone dimers possessing potent antibacterial activity against drug-resistant strains of Staphylococcus aureus. (2003) (49)
- Pharmacokinetics of Single-Dose Daptomycin in Patients with Suspected or Confirmed Neurological Infections (2011) (49)
- Recommendations for Training and Certification for Pharmacists Practicing, Mentoring, and Educating in Infectious Diseases Pharmacotherapy (2009) (49)
- Treatment of Vancomycin-Resistant Enterococcus faeciumwith RP 59500 (Quinupristin-Dalfopristin) Administered by Intermittent or Continuous Infusion, Alone or in Combination with Doxycycline, in an In Vitro Pharmacodynamic Infection Model with Simulated Endocardial Vegetations (1998) (49)
- Ofloxacin Clinical Pharmacokinetics (1992) (48)
- Telavancin: An Antimicrobial with a Multifunctional Mechanism of Action for the Treatment of Serious Gram‐Positive Infections (2008) (48)
- Epidemiology of Acute Kidney Injury among Patients Receiving Concomitant Vancomycin and Piperacillin-Tazobactam: Opportunities for Antimicrobial Stewardship (2016) (48)
- Evaluation of Bactericidal Activities of LY333328, Vancomycin, Teicoplanin, Ampicillin-Sulbactam, Trovafloxacin, and RP59500 Alone or in Combination with Rifampin or Gentamicin against Different Strains of Vancomycin-Intermediate Staphylococcus aureus by Time-Kill Curve Methods (1999) (48)
- Analysis of Vancomycin Population Susceptibility Profiles, Killing Activity, and Postantibiotic Effect against Vancomycin-Intermediate Staphylococcus aureus (1999) (48)
- Guidance for the Knowledge and Skills Required for Antimicrobial Stewardship Leaders (2014) (47)
- Combination antimicrobial therapy for bacterial infections. Guidelines for the clinician. (1996) (47)
- Evaluation of Vancomycin and Daptomycin Potency Trends (MIC Creep) against Methicillin-Resistant Staphylococcus aureus Isolates Collected in Nine U.S. Medical Centers from 2002 to 2006 (2010) (46)
- Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus (1991) (46)
- Current and prospective treatments for multidrug-resistant gram-positive infections (2013) (46)
- Mechanisms of in-vitro-selected daptomycin-non-susceptibility in Staphylococcus aureus. (2011) (46)
- Activities of Newer Fluoroquinolones against Ciprofloxacin-Resistant Streptococcus pneumoniae (2001) (46)
- Activities of Trovafloxacin, Gatifloxacin, Clinafloxacin, Sparfloxacin, Levofloxacin, and Ciprofloxacin against Penicillin-Resistant Streptococcus pneumoniae in an In Vitro Infection Model (2000) (45)
- Activities of LY333328 and Vancomycin Administered Alone or in Combination with Gentamicin against Three Strains of Vancomycin-Intermediate Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model (2000) (45)
- Prospective evaluation of red man syndrome in patients receiving vancomycin. (1993) (45)
- Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agents. (2012) (44)
- Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study. (2020) (44)
- Quinupristin/Dalfopristin (RP 59500): A New Streptogramin Antibiotic (1995) (44)
- Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations (2014) (43)
- Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram‐Positive Infections (2015) (42)
- Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes. (2014) (41)
- β-Lactams Enhance Daptomycin Activity against Vancomycin-Resistant Enterococcus faecalis and Enterococcus faecium in In Vitro Pharmacokinetic/Pharmacodynamic Models (2015) (41)
- Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus. (2013) (41)
- Bacteriophage Therapeutics: A Primer for Clinicians on Phage‐Antibiotic Combinations (2019) (41)
- In-vitro bactericidal activity of quinupristin/dalfopristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. (1997) (41)
- Pharmacodynamics of RP 59500 alone and in combination with vancomycin against Staphylococcus aureus in an in vitro-infected fibrin clot model (1995) (41)
- Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE. (2015) (41)
- Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline. (2004) (40)
- Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism (2017) (40)
- Evaluation of Endocarditis Caused by Methicillin-Susceptible Staphylococcus aureus Developing Nonsusceptibility to Daptomycin (2007) (40)
- Treatment of Methicillin-Resistant Staphylococcus aureus Infections with a Minimal Inhibitory Concentration of 2 μg/mL to Vancomycin: Old (Trimethoprim/Sulfamethoxazole) versus New (Daptomycin or Linezolid) Agents (2012) (39)
- The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA. (2015) (39)
- Evaluation of Ceftaroline Activity versus Daptomycin (DAP) against DAP-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Strains in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2011) (39)
- Influence of Platelets and Platelet Microbicidal Protein Susceptibility on the Fate of Staphylococcus aureusin an In Vitro Model of Infective Endocarditis (2000) (39)
- Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments (2019) (38)
- Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia. (2015) (38)
- Monitoring Vancomycin Therapy (1986) (38)
- Evaluation of High-Dose Daptomycin Versus Vancomycin Alone or Combined with Clarithromycin or Rifampin Against Staphylococcus aureus and S. epidermidis in a Novel In Vitro PK/PD Model of Bacterial Biofilm (2014) (37)
- A Novel Approach Utilizing Biofilm Time-Kill Curves To Assess the Bactericidal Activity of Ceftaroline Combinations against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus (2014) (37)
- Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots (1996) (37)
- Pharmacodynamic Analysis of Daptomycin-Treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. (2018) (37)
- Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic Model (2008) (37)
- Absence of "red man syndrome" in patients being treated with vancomycin or high-dose teicoplanin (1992) (36)
- Antimicrobial Susceptibility and Staphylococcal Chromosomal Cassette mec Type in Community‐ and Hospital‐Associated Methicillin‐Resistant Staphylococcus aureus (2007) (35)
- Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2015) (35)
- Epidemiology of Vancomycin-Resistant Enterococcus faecalis: a Case-Case-Control Study (2012) (35)
- Comparison of a Rabbit Model of Bacterial Endocarditis and an In Vitro Infection Model with Simulated Endocardial Vegetations (2000) (35)
- Synthesis and antibacterial properties of (-)-nor-platencin. (2009) (34)
- Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model (2016) (34)
- Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model (1992) (34)
- Vancomycin‐Resistant Enterococci (1995) (34)
- Fluoroquinolone Resistance in Streptococcus pneumoniae: Area Under the Concentration-Time Curve/MIC Ratio and Resistance Development with Gatifloxacin, Gemifloxacin, Levofloxacin, and Moxifloxacin (2007) (34)
- Increased Theophylline Concentrations Secondary to Ciprofloxacin (1987) (33)
- Evaluation of daptomycin, telavancin, teicoplanin, and vancomycin activity in the presence of albumin or serum. (2008) (33)
- Pharmacodynamics of vancomycin and ampicillin alone and in combination with gentamicin once daily or thrice daily against Enterococcus faecalis in an in vitro infection model. (2000) (33)
- Implementation of an Antimicrobial Stewardship Pathway with Daptomycin for Optimal Treatment of Methicillin‐Resistant Staphylococcus aureus Bacteremia (2013) (33)
- Pharmacodynamic effects of extended dosing intervals of imipenem alone and in combination with amikacin against Pseudomonas aeruginosa in an in vitro model (1993) (33)
- Macrolides and staphylococcal biofilms. (2012) (33)
- Correlation of vancomycin and daptomycin susceptibility in Staphylococcus aureus in reference to accessory gene regulator (agr) polymorphism and function. (2007) (32)
- Pharmacodynamic Analysis of the Activity of Quinupristin-Dalfopristin against Vancomycin-ResistantEnterococcus faecium with Differing MBCs via Time-Kill-Curve and Postantibiotic Effect Methods (1998) (32)
- The effects of NorA inhibition on the activities of levofloxacin, ciprofloxacin and norfloxacin against two genetically related strains of Staphylococcus aureus in an in-vitro infection model. (1999) (32)
- Evaluation of vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus and heterogeneously vancomycin-intermediate S. aureus in an in vitro pharmacokinetic/pharmacodynamic model with simulated endocardial vegetations. (2008) (32)
- Evaluation of the Novel Combination of High-Dose Daptomycin plus Trimethoprim-Sulfamethoxazole against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus Using an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations (2012) (31)
- Pharmacodynamics of Cefepime Alone and in Combination with Various Antimicrobials against Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacodynamic Infection Model (2005) (31)
- Antimicrobial Susceptibility Tests (1982) (31)
- Clinical evaluation of teicoplanin fluorescence polarization immunoassay (1991) (30)
- In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium (1997) (30)
- Impact of the Combination of Daptomycin and Trimethoprim-Sulfamethoxazole on Clinical Outcomes in Methicillin-Resistant Staphylococcus aureus Infections (2015) (29)
- Ofloxacin: A Review (1989) (29)
- Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections (2020) (29)
- Activity of Oritavancin (LY333328), an Investigational Glycopeptide, Compared to That of Vancomycin against Multidrug-Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model (2001) (29)
- Single Daily Dosing of Aminoglycosides: A Commentary (1994) (28)
- Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with β-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions (2018) (28)
- Multidrug-resistant Pseudomonas aeruginosa lower respiratory tract infections in the intensive care unit: Prevalence and risk factors. (2017) (28)
- Cefazolin and Ertapenem, a Synergistic Combination Used To Clear Persistent Staphylococcus aureus Bacteremia (2016) (27)
- Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus: Does Vancomycin Heteroresistance Matter? (2016) (27)
- Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus Vertebral Osteomyelitis Cases Complicated by Bacteremia Treated with High-Dose Daptomycin and Trimethoprim-Sulfamethoxazole (2012) (27)
- Activity of Telavancin against Staphylococcus aureus Strains with Various Vancomycin Susceptibilities in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations (2009) (27)
- Bacteriophage-Antibiotic Combination Strategy: an Alternative against Methicillin-Resistant Phenotypes of Staphylococcus aureus (2020) (26)
- Impact of Different Antimicrobial Therapies on Clinical and Fiscal Outcomes of Patients with Bacteremia Due to Vancomycin-Resistant Enterococci (2014) (26)
- Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium (1993) (26)
- Epidemiology of Vancomycin-Resistant Enterococci with Reduced Susceptibility to Daptomycin (2012) (26)
- Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer (2018) (26)
- Pharmacologic and Bacteriologic Properties of SCH‐27899 (Ziracin), an Investigational Antibiotic from the Everninomicin Family (1999) (26)
- In vitro evaluation of ceftaroline alone and in combination with tobramycin against hospital-acquired meticillin-resistant Staphylococcus aureus (HA-MRSA) isolates. (2010) (25)
- Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis (1990) (25)
- Evaluation of Telavancin Activity versus Daptomycin and Vancomycin against Daptomycin-Nonsusceptible Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2011) (25)
- A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii (2014) (25)
- Accessory gene regulator dysfunction: an advantage for Staphylococcus aureus in health-care settings? (2009) (25)
- Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens (2020) (25)
- Novel approaches for the treatment of methicillin-resistant Staphylococcus aureus: using nanoparticles to overcome multidrug resistance. (2020) (24)
- Ceftobiprole: First Cephalosporin with Activity Against Methicillin‐Resistant Staphylococcus aureus (2009) (24)
- Individualized Adjustment of Vancomycin Dosage: Comparison with Two Dosage Nomograms (1986) (24)
- Evaluation of Eravacycline: A Novel Fluorocycline (2020) (24)
- High-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It (2014) (24)
- β-Lactam Combinations with Vancomycin Show Synergistic Activity against Vancomycin-Susceptible Staphylococcus aureus, Vancomycin-Intermediate S. aureus (VISA), and Heterogeneous VISA (2018) (24)
- Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections (2020) (24)
- Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. (2005) (23)
- Examining the Use of Ceftaroline in the Treatment of Streptococcus pneumoniae Meningitis with Reference to Human Cathelicidin LL-37 (2015) (23)
- Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus. (2008) (23)
- Beta-Lactams combinations with Vancomycin provide synergy against VSSA, hVISA, and VISA (2018) (23)
- Treatment of Ebola Virus Disease (2015) (23)
- An evaluation of the bactericidal activity of ampicillin/sulbactam, piperacillin/tazobactam, imipenem or nafcillin alone and in combination with vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) in time-kill curves with infected fibrin clots. (1997) (23)
- Growing Prevalence of Vancomycin-Resistant Enterococcus faecalis in the Region with the Highest Prevalence of Vancomycin-Resistant Staphylococcus aureus (2011) (23)
- Telavancin Demonstrates Activity against Methicillin-Resistant Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin, Daptomycin, and Linezolid in Broth Microdilution MIC and One-Compartment Pharmacokinetic/Pharmacodynamic Models (2015) (23)
- Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center (2015) (22)
- In vitro time-kill analysis of oritavancin against clinical isolates of methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin. (2011) (22)
- Characterizing Vancomycin-Resistant Enterococcus Strains with Various Mechanisms of Daptomycin Resistance Developed in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2011) (22)
- Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa (2021) (22)
- Impact of Enterococcus faecalis on the Bactericidal Activities of Arbekacin, Daptomycin, Linezolid, and Tigecycline against Methicillin-Resistant Staphylococcus aureus in a Mixed-Pathogen Pharmacodynamic Model (2006) (21)
- In Vitro Activity of the New Multivalent Glycopeptide-Cephalosporin Antibiotic TD-1792 against Vancomycin-Nonsusceptible Staphylococcus Isolates (2010) (21)
- Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci (2016) (21)
- Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa (2022) (20)
- Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection (2019) (20)
- Alanine aminopeptidase and beta 2-microglobulin excretion in patients receiving vancomycin and gentamicin (1987) (20)
- Antimicrobial Stewardship Opportunities in Critically Ill Patients with Gram-Negative Lower Respiratory Tract Infections: A Multicenter Cross-Sectional Analysis (2017) (20)
- Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs) (2017) (19)
- Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation (2013) (19)
- Once‐Daily Aminoglycoside in the Treatment of Enterococcus faecalis Endocarditis: Case Report and Review (2000) (19)
- Preliminary, Real-world, Multicenter Experience With Omadacycline for Mycobacterium abscessus Infections (2021) (19)
- Evaluation of dalbavancin, tigecycline, minocycline, tetracycline, teicoplanin and vancomycin against community-associated and multidrug-resistant hospital-associated meticillin-resistant Staphylococcus aureus. (2010) (18)
- Antimicrobial stewardship - Roundtable discussion (2006) (18)
- Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model (1997) (18)
- Nephrotoxicity Comparison of Two Commercially Available Generic Vancomycin Products (2015) (18)
- The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the Horse (2020) (18)
- Vancomycin: Over 50 Years Later and Still a Work in Progress (2013) (18)
- Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii (2016) (18)
- CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis (1992) (17)
- Early Experience With Eravacycline for Complicated Infections. (2020) (17)
- Influence of antibiotic and E5 monoclonal immunoglobulin M interactions on endotoxin release from Escherichia coli and Pseudomonas aeruginosa (1996) (17)
- Bacteriophage-Antibiotic Combinations for Enterococcus faecium with Varying Bacteriophage and Daptomycin Susceptibilities (2020) (17)
- Bactericidal activities of cefprozil, penicillin, cefaclor, cefixime, and loracarbef against penicillin-susceptible and -resistant Streptococcus pneumoniae in an in vitro pharmacodynamic infection model (1996) (17)
- Antimicrobial resistance prevention initiative: Proceedings of an expert panel on resistance - Roundtable discussion (2006) (17)
- Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study. (2012) (17)
- Risk factors for and epidemiology of community-onset vancomycin-resistant Enterococcus faecalis in southeast Michigan. (2013) (17)
- Sequential Evolution of Vancomycin-Intermediate Resistance Alters Virulence in Staphylococcus aureus: Pharmacokinetic/Pharmacodynamic Targets for Vancomycin Exposure (2015) (17)
- Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA (2018) (17)
- Dalbavancin Alone and in Combination with Ceftaroline against Four Different Phenotypes of Staphylococcus aureus in a Simulated Pharmacodynamic/Pharmacokinetic Model (2019) (17)
- Erratum: The triazole antifungal agents: A review of itraconazole and fluconazole (Pharmacotherapy (1990) 10 (146-153)) (1990) (16)
- In Vitro Activities of a Novel Cephalosporin, CB-181963 (CAB-175), against Methicillin-Susceptible or -Resistant Staphylococcus aureus and Glycopeptide-Intermediate Susceptible Staphylococci (2004) (16)
- Evaluation of daptomycin activity against Staphylococcus aureus in an in vitro pharmacodynamic model under normal and simulated impaired renal function. (2006) (16)
- Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model (2016) (16)
- A Multicenter Evaluation of Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections (2020) (16)
- Virulence characteristics of community-associated Staphylococcus aureus and in vitro activities of moxifloxacin alone and in combination against community-associated and healthcare-associated meticillin-resistant and -susceptible S. aureus. (2008) (16)
- Efficacy of Trovafloxacin against Experimental Staphylococcus aureus Endocarditis (1998) (16)
- Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis (1991) (15)
- Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. (1986) (15)
- Evaluation of Vancomycin Population Susceptibility Analysis Profile as a Predictor of Outcomes for Patients with Infective Endocarditis Due to Methicillin-Resistant Staphylococcus aureus (2014) (15)
- Combination of Vancomycin or Daptomycin and Beta‐lactam Antibiotics: A Meta‐analysis (2020) (15)
- Teaching an Old Class New Tricks: A Novel Semi-Synthetic Aminoglycoside, Plazomicin (2019) (15)
- Ceftaroline Increases Membrane Binding and Enhances the Activity of Daptomycin against Daptomycin-Nonsusceptible Vancomycin-Intermediate Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model (2013) (15)
- Ceftaroline fosamil for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection (2012) (14)
- Mutations in cdsA and pgsA Correlate with Daptomycin Resistance in Streptococcus mitis and S. oralis (2018) (14)
- Ceftaroline Fosamil for Methicillin-Resistant Staphylococcus aureus Pulmonary Exacerbation in a Pediatric Cystic Fibrosis Patient. (2014) (14)
- In Vitro Antibacterial Activity of Cefiderocol against Multidrug-Resistant Acinetobacter baumannii (2021) (14)
- Trimethoprim/Sulfamethoxazole-Induced Tremor in a Patient with AIDS (1998) (14)
- Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations (2018) (13)
- Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections (2021) (13)
- Successful treatment of a left ventricular assist device infection with daptomycin non‐susceptible methicillin‐resistant Staphylococcus aureus: case report and review of the literature (2012) (13)
- The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin (2019) (13)
- Evaluation of dalbavancin alone and in combination with &bgr;-lactam antibiotics against resistant phenotypes of Staphylococcus aureus (2018) (13)
- Rhodococcus equi Pneumonia in a Patient with Human Immunodeficiency Virus: Case Report and Review (2001) (13)
- Spiramycin in the Treatment of Cryptosporidiosis (1987) (13)
- The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy (2020) (13)
- Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model (2020) (13)
- Comparison of Serum Sampling Methods for Determining Vancomycin Dosage Regimens (1988) (12)
- Ceragenins: Cholic Acid Based Mimics of Antimicrobial Peptides (2009) (12)
- Acceptance of Pharmacist-Driven Antimicrobial Stewardship Recommendations With Differing Levels of Physician Involvement in a Children’s Hospital (2017) (12)
- Comparison of clinical outcomes and risk factors in polymicrobial versus monomicrobial enterococcal bloodstream infections. (2016) (12)
- Impact of cefazolin co-administration with vancomycin to reduce development of vancomycin-intermediate Staphylococcus aureus. (2018) (12)
- Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis (2020) (12)
- Impact of Dose De-Escalation and Escalation on Daptomycin's Pharmacodynamics against Clinical Methicillin-Resistant Staphylococcus aureus Isolates in an In Vitro Model (2011) (12)
- Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2011) (11)
- Therapeutic options for Gram-positive infections. (2001) (11)
- Linezolid and Vancomycin, Alone and in Combination with Rifampin, Compared with Moxifloxacin against a Multidrug-Resistant and a Vancomycin-Tolerant Streptococcus pneumoniae Strain in an In Vitro Pharmacodynamic Model (2003) (11)
- Coagulase-Negative Staphylococci: Incidence, Pathogenicity, and Treatment in the 1990S (1990) (11)
- Hematological Effects Associated with Beta-Lactam Use (1986) (11)
- Pharmacodynamics: relation to antimicrobial resistance. (2006) (11)
- Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI) (2017) (11)
- Evaluation of Ceftaroline Activity versus Ceftriaxone against Clinical Isolates of Streptococcus pneumoniae with Various Susceptibilities to Cephalosporins in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2012) (11)
- In vitro pharmacokinetic/pharmacodynamic activity of NXL103 versus clindamycin and linezolid against clinical Staphylococcus aureus and Streptococcus pyogenes isolates. (2011) (11)
- Teicoplanin pharmacodynamics in reference to the accessory gene regulator (agr) in Staphylococcus aureus using an in vitro pharmacodynamic model. (2008) (11)
- COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options (2021) (11)
- Comparative Epidemiology of Bacteremia due to Methicillin-Resistant Staphylococcus aureus between Older and Younger Adults A Propensity Score Analysis (2013) (10)
- Susceptibility studies of piperazinyl-cross-linked fluoroquinolone dimers against test strains of Gram-positive and Gram-negative bacteria. (2006) (10)
- Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model (2019) (10)
- Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It’s Complicated (2019) (10)
- β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus (2016) (10)
- Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis (1989) (10)
- Novel application of published risk factors for methicillin-resistant S. aureus in acute bacterial skin and skin structure infections. (2018) (10)
- Increased bacterial resistance: PROTEKT US--an update. (2004) (10)
- Linezolid, Levofloxacin, and Vancomycin Against Vancomycin‐Tolerant and Fluoroquinolone‐Resistant Streptococcus pneumoniae in an In Vitro Pharmacodynamic Model (2003) (9)
- New Milestones Achieved in Fluoroquinolone Safety (2001) (9)
- Ceftaroline plus Avibactam Demonstrates Bactericidal Activity against Pathogenic Anaerobic Bacteria in a One-Compartment In Vitro Pharmacokinetic/Pharmacodynamic Model (2013) (9)
- Oxazolidinones: new players in the battle against multi-resistant Gram-positive bacteria (2001) (9)
- Evaluation of Daptomycin Non-Susceptible Staphylococcus aureus for Stability, Population Profiles, mprF Mutations, and Daptomycin Activity (2013) (8)
- Enoxacin: a new fluoroquinolone. (1989) (8)
- Trends in and Predictors of Carbapenem Consumption across North American Hospitals: Results from a Multicenter Survey by the MAD-ID Research Network (2019) (8)
- Parenteral Fosfomycin for the Treatment of Multidrug Resistant Bacterial Infections: The Rise of the Epoxide (2019) (8)
- Impact of COVID-19 pandemic on training of pharmacy residents and fellows: Results from a national survey of postgraduate pharmacy trainees (2021) (8)
- Effect of Human Serum on Killing Activity of Vancomycin and Teicoplanin against Staphylococcus aureus (1994) (8)
- Pulsatile delivery of amoxicillin against Streptococcus pneumoniae. (2004) (8)
- Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model (2020) (8)
- Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis (2017) (7)
- Clinical Pharmacology of Bacteriophage Therapy: A Focus on Multidrug-Resistant Pseudomonas aeruginosa Infections (2021) (7)
- Averting the post-antibiotic era: successful use of meropenem/vaborbactam for carbapenem-resistant Serratia marcescens and Enterobacter aerogenes bacteraemia in a haemodialysis patient (2018) (7)
- Daptomycin (2004) (7)
- Time-kill determination of the bactericidal activity of telavancin and vancomycin against clinical methicillin-resistant Staphylococcus aureus isolates from cancer patients. (2017) (7)
- Treatment of Methicillin-Resistant Staphylococcus aureus (MRSA) Pneumonia with Ceftaroline Fosamil in a Patient with Inhalational Thermal Injury (2015) (7)
- In Vitro Synergy of Colistin in Combination with Meropenem or Tigecycline against Carbapenem-Resistant Acinetobacter baumannii (2021) (7)
- Comparative efficacies of imipenem-cilastatin and vancomycin in experimental aortic valve endocarditis due to methicillin resistant Staphylococcus aureus. (1988) (7)
- Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus (2019) (7)
- Evaluation of Pharmacodynamic Interactions Between Telavancin and Aztreonam or Piperacillin/Tazobactam Against Pseudomonas aeruginosa, Escherichia coli and Methicillin-Resistant Staphylococcus aureus (2016) (7)
- Pharmacodynamics of daptomycin when prescribed in combination with other antibiotics for treatment of enterococcal bacteremia. (2019) (6)
- Evaluation of Telavancin Alone and Combined with Ceftaroline or Rifampin against Methicillin-Resistant Staphylococcus aureus in an In Vitro Biofilm Model (2018) (6)
- A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli (2020) (6)
- Antimicrobial Stewardship (2007) (6)
- COVID‐19: Important Therapy Considerations and Approaches in this Hour of Need (2020) (6)
- Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children (2011) (6)
- Transdermal Clonidine (1986) (6)
- Laboratory Tests to Direct Antimicrobial Pharmacotherapy (2014) (6)
- Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections (2018) (6)
- Teicoplanin Pharmacokinetics inIntravenous DrugAbusers Being Treated forBacterial Endocarditis (1991) (6)
- Omeprazole‐Induced Exfoliative Dermatitis (1998) (6)
- Vancomycin-resistant Enterococcus: Infectious endocarditis treatment (1999) (6)
- Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections (2019) (6)
- Mechanistic Insights into the Differential Efficacy of Daptomycin plus β-Lactam Combinations against Daptomycin-Resistant Enterococcus faecium. (2020) (6)
- Genomic characterization of an extensively drug-resistant KPC-2-producing Klebsiella pneumoniae ST855 (CC258) only susceptible to ceftazidime-avibactam isolated in Brazil. (2017) (6)
- Eradication of Biofilm-Mediated Methicillin-Resistant Staphylococcus aureus Infections In Vitro: Bacteriophage-Antibiotic Combination (2022) (6)
- Cefixime (1990) (6)
- Combinations of (lipo)glycopeptides with β-lactams against MRSA: susceptibility insights. (2020) (6)
- Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study (2021) (5)
- Parenteral Fosfomycin: A New Ally in the Fight Against Multidrug-Resistant Bacterial Pathogens. (2019) (5)
- Global Antimicrobial Stewardship: Challenges and Successes from Frontline Stewards (2015) (5)
- Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam (2020) (5)
- Comparative in vitro activities of LY191145, a new glycopeptide, and vancomycin against Staphylococcus aureus and Staphylococcus-infected fibrin clots (1995) (5)
- Opportunities for antibiotic stewardship among carbapenem-treated patients within 18 North American hospitals. (2020) (5)
- Vancomycin Area Under the Curve to Predict Timely Clinical Response in the Treatment of Methicillin-resistant Staphylococcus aureus Complicated Skin and Soft Tissue Infections. (2020) (5)
- Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection versus illusion? (2016) (5)
- Evaluation of Bacteriophage Cocktails Alone and in Combination with Daptomycin against Daptomycin-Nonsusceptible Enterococcus faecium (2021) (4)
- Exebacase in Addition to Daptomycin against MRSA (2021) (4)
- 2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (2019) (4)
- Introduction to the Special Issue on Antimicrobial Stewardship (2012) (4)
- Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin (2019) (4)
- Bacteriophage AB-SA01 Cocktail in Combination with Antibiotics against MRSA-VISA Strain in an In Vitro Pharmacokinetic/Pharmacodynamic Model (2020) (4)
- Activities of Trovafloxacin and Ampicillin-Sulbactam Alone or in Combination versus Three Strains of Vancomycin- IntermediateStaphylococcus aureus in an In Vitro Pharmacodynamic Infection Model (2000) (4)
- Summary of the ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis. ASHP Commission on Therapeutics. (1990) (4)
- Pharmacokinetics and Pharmacodynamics of Ceftizoxime in Patients with Dosages Adjusted for Renal Function (2000) (4)
- O32 Increasing prevalence of glycopeptide hetero-resistant Staphylococcus aureus from the Detroit Metropolitan Area over a 20-year period (1986–2006) (2007) (4)
- Single Dose Enoxacin for the Treatment of Uncomplicated Urogenital Gonorrhea (1989) (4)
- Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms (2022) (4)
- The Optimal Use of the Polymyxins Before Their Time Is Up (2019) (4)
- Nonlinear Theophylline Kinetics (1984) (4)
- Clonal Pan or Extensively Drug-Resistant KPC-2-Producing ST437 Klebsiella pneumoniae Causing Untreatable Infections Evidenced by In Vitro Synergy Testing (2016) (4)
- A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia (2019) (4)
- Validity of 2020 vancomycin consensus guidelines and further guidance for practical application. (2021) (3)
- Comment on: AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. (2021) (3)
- Teicoplanin vs vancomycin: cost-effectiveness comparisons. (1993) (3)
- Stability and antimicrobial activity of gentamicin sulfate, tobramycin sulfate and amikacin sulfate in polypropylene syringes for use in once-daily aminoglycoside therapy. (1996) (3)
- Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin (1991) (3)
- Haloperidol-Associated Hyperthermia (1985) (3)
- In Vitro Pharmacodynamic Effects of Concentration, pH, and Growth Phase on Serum Bactericidal Activities of Daptomycin and Vancomycin (1993) (3)
- Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection (2021) (3)
- Phage Cocktails with Daptomycin and Ampicillin Eradicates Biofilm-Embedded Multidrug-Resistant Enterococcus faecium with Preserved Phage Susceptibility (2022) (3)
- Folate Functionalized Lipid Nanoparticles for Targeted Therapy of Methicillin-Resistant Staphylococcus aureus (2021) (3)
- International Validation of a Methicillin-Resistant Staphylococcus aureus Risk Assessment Tool for Skin and Soft Tissue Infections (2022) (2)
- Clinical Outcomes of Eravacycline in Patients Treated Predominately for Carbapenem-Resistant Acinetobacter baumannii (2022) (2)
- Development of a Risk-Scoring Tool to Determine Appropriate Level of Care in Acute Bacterial Skin and Skin Structure Infections in an Acute Healthcare Setting (2018) (2)
- Novel Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Necrotizing Pneumonia Complicated by Empyema: A Case Report (2022) (2)
- Clinical Characteristics Associated with Bacterial Bloodstream Coinfection in COVID-19 (2022) (2)
- Bacteriophage‐antibiotic combination therapy for multidrug‐resistant Pseudomonas aeruginosa: In vitro synergy testing (2022) (2)
- Intravitreal ganciclovir for cytomegalovirus retinitis in AIDS patients. (1992) (2)
- Antimicrobial Susceptibility Among Respiratory Tract Pathogens From the Northern States of the USA: Data From Year 1 of the PROTEKT US Surveillance Program (2000-2001) (2005) (2)
- Pulsatile Delivery of Clarithromycin Alone or in Combination with Amoxicillin against Streptococcus pneumoniae (2006) (2)
- Reply to Koehler, et al. (2019) (2)
- Bactericidal activity of ceftaroline, vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus isolates from cancer patients. (2019) (2)
- Biofilm Time-Kill Curves to Assess the Bactericidal Activity of Daptomycin Combinations against Biofilm-Producing Vancomycin-Resistant Enterococcus faecium and faecalis (2021) (2)
- In vitro activity of CL 331,002, a new glycylcycline compound against Staphylococcus aureus and Enterococcus faecium (1997) (2)
- Pathogen-Specific Clinical Trials: A New Paradigm in Clinical Trials for Multidrug-Resistant Organisms (2018) (2)
- 615. Daptomycin (DAP) Synergy with β-Lactams in DAP-Resistant (DAP-R) E. faecium (Efm) Is Dependent On PBP5 Sequence and β-Lactam-binding Affinity (2019) (1)
- Roundtable discussion. Maximizing potential cost benefits of teicoplanin through appropriate usage. (1993) (1)
- Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA) (2017) (1)
- Reply to Panday and Sturkenboom (2009) (1)
- Oral treatment of gonorrhea and chlamydia. (1994) (1)
- Subminimum Inhibitory Concentrations of Antimicrobials (1983) (1)
- Delafloxacin in Acute Bacterial Skin and Skin Structure Infections (2019) (1)
- Real-World, Multicenter Case Series of Patients Treated with Oral Omadacycline for Resistant Gram-Negative Pathogens (2022) (1)
- Determination of NAT2 Activity in the US Population by Use of Caffeine Metabolite Ratios in Spot Urine Samples: NHANES 2009–2010 (2016) (1)
- Treatment of Pseudomonal Endocarditis with High-Dose Aminoglycosides (1982) (1)
- 638. The Impact of in vitro Synergy Between Colistin and Meropenem on Clinical Outcomes in Invasive Carbapenem-resistant Gram-negative Infections: A Report from the OVERCOME Trial (2021) (1)
- Sensitivity Testing and the Inoculum Effect (1984) (1)
- Multicenter Study of the Real-World Use of Ceftaroline versus Vancomycin for Acute Bacterial Skin and Skin Structure Infections (2019) (1)
- Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure (2023) (1)
- Reply to Cheng and Chuang. (2019) (1)
- 1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia (2018) (1)
- Assessment of Differences in Antimicrobial Effect Determined with Two In Vitro Pharmacodynamic Models: Impact of Surface Area to Volume Ratio (2003) (1)
- Predicting and Defining Vancomycin Efficacy: Program Overview (2006) (1)
- 1061. Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia (2018) (1)
- Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study (2018) (1)
- Evaluation of Bacteriophage-Antibiotic Combination Therapy for Biofilm-Embedded MDR Enterococcus faecium (2022) (1)
- 1290. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial and Gram-Negative Infections: A Multicenter Evaluation (2020) (1)
- ASHP therapeutic guidelines on nonsurgical antimicrobial prophylaxis (1990) (1)
- P2064 Evaluation of daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro phar-macodynamic model with simulated endocardial vegetations (2007) (1)
- Questions on Vancomycin dosing. (2020) (1)
- Activity of the Lactate Dehydrogenase Inhibitor Oxamic Acid against the Fermentative Bacterium Streptococcus mitis/oralis: Bactericidal Effects and Prevention of Daptomycin Resistance In Vitro and in an Ex Vivo Model (2022) (1)
- Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis. (2015) (1)
- Novel Influenza A (H1N1) Presenting as an Acute Febrile Encephalopathy in a Mother and Daughter (2009) (1)
- Nephrotoxicity of Vancomycin in Combination with Beta-lactam Agents: Ceftolozane-tazobactam vs. Piperacillin-tazobactam. (2022) (1)
- Vancomycin‐Resistant Enterococci (1996) (1)
- Pharmacodynamics of Once-Daily Amikacin in Various Combinations with Cefepime, Aztreonam, and Ceftazidime against Pseudomonas aeruginosa in an In Vitro Infection Model (1993) (1)
- Cefepime: part of the new generation. (1994) (1)
- 1297. In-Vitro Antibacterial Activities of Cefiderocol (S-649266) Alone and With the Addition of Beta-Lactamase Inhibitors Against Multidrug-resistant Acinetobacter baumannii (2020) (1)
- Erratum: Outcome assessment of minimizing vancomycin monitoring and dosing adjustments (Pharmacotherapy (1999) 19:3 (257-266)) (1999) (1)
- 1546. Efficacy of Daptomycin Combinations Against Daptomycin-Resistant Enterococcus faecium Differs by β-lactam (2019) (1)
- Daptomycin: Pharmacokinetic, Pharmacodynamic, and Dose Optimization (2014) (1)
- Outbreak report of polymyxin-carbapenem-resistant Klebsiella pneumoniae causing untreatable infections evidenced by synergy tests and bacterial genomes. (2023) (0)
- 2433. Evaluation of Meropenem (MEM) in Combination With Colistin (COL) Against Colistin-Resistant Extensively Drug-Resistant (XRD) Gram-Negative Bacteria (2018) (0)
- 686. Comparing Treatments of Methicillin-Resistant Staphylococcus aureus Infective Endocarditis by People Who Inject Drugs (2021) (0)
- Urine caffeine and caffeine metabolites as indicators of dietary caffeine exposure and metabolism phenotypes in population studies (245.1) (2014) (0)
- Reply to Cataldo et al (2011) (0)
- Letter from the Editor (2013) (0)
- Incorrect or unsubstantiated indications listed for selected antimicrobials in the Physicians' Desk Reference. (1979) (0)
- 1288. Evaluation of Predictors for Clinical Success in Patients Treated with Eravacycline for Various Infections (2021) (0)
- A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections (2022) (0)
- CEFTOBIPROLE : FIRST CEPHALOSPORIN WITH ACTIVITY AGAINST MRSA Vidaillac and Rybak Mechanism of Action (2009) (0)
- Pharmacodynamic Effects ofExtended Dosing Intervals of Imipenem AloneandinCombination withAmikacin against Pseudomonas aeruginosa inanInVitro Model (1993) (0)
- Genomic Pathways Associated with Daptomycin (DAP) Resistance in DAP-Susceptible Enterococcus faecium Harboring Substitutions in LiaFSR (2017) (0)
- Oral stepdown in Gram‐positive bloodstream infections: A step in the right direction (2023) (0)
- Gram-positive Bacteria (2014) (0)
- Association of Demographic, Lifestyle, Physiologic, and Intake Variables With Urine Caffeine and Caffeine Metabolites in the US Population (2015) (0)
- P41 AN ALTERNATIVE SUSCEPTIBILITY METHOD AS PREDICTOR OF CLINICAL RESPONSE TO VANCOMYCIN (VAN) WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) INFECTIVE ENDOCARDITIS (IE) (2013) (0)
- A Novel Approach Utilizing Biofilm Time Kill Curves in Assessing the 2 Bactericidal Activity of Ceftaroline Combinations Against Biofilm 3 (2014) (0)
- 1575. Predictors of Negative Clinical Outcomes among Patients treated with Meropenem-Vaborbactam for Serious Gram-Negative Bacterial Infections: Impact of Delayed Appropriate Antibiotic Selection (2020) (0)
- Title: A Large Retrospective Evaluation of the Effectiveness and Safety of (2014) (0)
- 200. Real-World Experience with Dalbavancin for Complicated Gram-Positive Infections: A Multicenter Evaluation (2019) (0)
- SY.2.2 HIGH–DOSE DAPTOMYCIN IN THE THERAPY OF STAPHYLOCOCCAL INFECTIVE ENDOCARDITIS AND WHEN TO APPLY IT (2013) (0)
- Sulbactam-durlobactam: A Novel β-lactam-β-lactamase Inhibitor Combination Targeting Carbapenem-Resistant Acinetobacter baumannii Infections. (2023) (0)
- 132. Evaluation Phage Cocktails in Combination with Ciprofloxacin Against Multidrug-Resistant Pseudomonas aeruginosa Overexpressing MexAB-OprM Efflux Systems (2021) (0)
- Developing Nonsusceptibility to Daptomycin (2007) (0)
- of Patient Outcomes with Methicillin-Resistant Staphylococcus aureus Infective (2014) (0)
- Case Study and Panel Discussion (2007) (0)
- Comparative efficacy of trovafloxacin and vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits (1997) (0)
- Risk Factors for Vancomycin-resistant Enterococcus faecalis bacteremia: A Case-Case-Control Study (2012) (0)
- 1643. Pharmacodynamics (PD) of Daptomycin (DAP) in Combination Therapy for Enterococcal Bloodstream Infection (BSI) (2018) (0)
- 1082. Real-World Experience with Omadacycline for Nontuberculous Mycobacterial Infections: A Multicenter Evaluation (2021) (0)
- Avoid Las Vegas as a meeting site for ASHP [4] (1991) (0)
- Erratum: In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin (Antimicrobial Agents and Chemotherapy 36:12 (2710)) (1993) (0)
- Roundtable discussion. Cost justification of innovative drugs through assessment of total health care costs. (1993) (0)
- 630. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem (2021) (0)
- Oscar A. Carretero, Md Abstracts Abstract No. 1 (student) Title: Comparing Two Methods for Detection of Sepsis Pathogens: Roll Plate and Direct Rt-pcr (2013) (0)
- 1422. A Multi-Center Evaluation of Omadacycline for Multi-Drug Resistant Infections (2022) (0)
- High-dose Cefepime vs Carbapenems for Bacteremia Caused by Enterobacterales With Moderate to High Risk of Clinically Significant AmpC β-lactamase Production (2023) (0)
- 1691. Bacteriophage and Protein Synthesis Pathway Inhibitor Combinations: Antibiotic mechanism of action drives antagonistic interactions (2022) (0)
- 679. Traditional vs. Alternative Agents in Patients with Lower Respiratory Tract Infections Caused by Carbapenem-Resistant Pseudomonas aeruginosa Susceptible to Traditional Agents (2022) (0)
- 2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections (2019) (0)
- SINGLEDAILY DOSING OFAMINOGLYCOSIDES: A COMMENrARY (1994) (0)
- 2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms (2018) (0)
- Predicting and Defining Vancomycin Efficacy: Posttest and Program Evaluation (2006) (0)
- Risk Factors for the Isolation of Vancomycin-Resistant Enterococcus Faecalis from Wound Site: A Case-Case Control Analysis (2012) (0)
- Agenda: Key Note Speaker: Abstracts Title the Design and Implementation of a Multidisciplinary, Student-run, Free Diabetes Education Wellness Clinic (2013) (0)
- 289. International Validation of a Methicillin-Resistant Staphylococcus aureus (MRSA) Risk Assessment Tool for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (2018) (0)
- Fosamil Therapy Effectiveness and Safety of Ceftaroline Large Retrospective Evaluation of the (2014) (0)
- 1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus (2019) (0)
- Pharmacodynamics ofOnce-Daily Amikacin inVarious Combinations withCefepime, Aztreonam, andCeftazidime against Pseudomonas aerugnosa inanInVitro Infection Model (1992) (0)
- 1399. Efficacy of Daptomycin Combination with β-Lactams for Daptomycin-resistant Enterococcus faecium Harboring LiaSR Substitutions (2018) (0)
- Independent risk factors for the co-colonization of vancomycin-resistant Enterococcus faecalis and methicillin-resistant Staphylococcus aureus in the region most endemic for vancomycin-resistant Staphylococcus aureus isolation (2013) (0)
- 1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI) (2019) (0)
- PK/PD Considerations for Vancomycin and Daptomycin (2017) (0)
- 2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections (2018) (0)
- Henry Ford Health System (2020) (0)
- 1542. The Evaluation of the In Vitro Synergy of Colistin in Combination with Meropenem and Tigecycline against 50 Multi-Drug-resistant Acinetobacter baumannii strains (2019) (0)
- 1073. Predictors of Vancomycin Switch or Escalation in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection (2018) (0)
- Pharmacokinetics andBactericidal RatesofDaptomycin and Vancomycin inIntravenous DrugAbusersBeingTreated forGram-Positive Endocarditis andBacteremia (1992) (0)
- Incorporation of Community-Associated Methicillin-Resistant Staphylococcus aureus (CAMRSA) into the Hospital Setting: An Outcome Assessment (2005) (0)
- 442. Risk Score for Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections (2019) (0)
- Principal Components Analysis of Urine Caffeine and Caffeine Metabolites in the US Population (2015) (0)
- Epidemiology of Community-acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA ) with Staphylococcal Cassette Chromosome Mec (SCC mec ) Type IV at an Urban Teaching Hospital (2004) (0)
- A new assay to determine Oritavancin concentrations (2010) (0)
- Development ofResistance toFleroxacin during Therapy ofExperimental Methicillin-Susc eptible Staphylococcus aureus Endocarditis (1991) (0)
- 276Molecular Epidemiology of MRSA and VRE Co-colonization among Hospitalized Adults in Detroit (2014) (0)
- All-Cause Readmission Following Treatment With Linezolid for MRSA-ABSSSI: A Propensity Score Analysis (2015) (0)
- In Vitro Activity of the New Multivalent Glycopeptide-Cephalosporin Antibiotic TD-1792 against Vancomycin-Nonsusceptible Staphylococcus Isolates (cid:1) (2010) (0)
- Synergy between gemifloxacin and trimethoprim/sulfamethoxazole against community-associated methicillin-resistant Staphylococcus aureus (2008) (0)
- A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia (2019) (0)
- Antimicrobial Resistance : A focus on Gram-Negative Bacterial Resistant Threats (2019) (0)
- Vancomycin Exposure Predicts Early Clinical Response in Complicated Skin and Soft Tissue Infections Caused by Methicillin-Resistant Staphylococcus aureus (2015) (0)
- 1577. Real-World, Multicenter Experience with Eravacycline for Various Infections (2020) (0)
- Evaluation of Ceftaroline (CPT) Activity Against Heteroresistant Vancomycin 1 Intermediate Staphylococcus aureus (hVISA) and VISA Methicillin-Resistant S. 2 aureus (MRSA) Strains in an In Vitro Pharmacokinetic/Pharmacodynamic (PK/PD) 3 Model: Exploring the “Seesaw Effect” (2013) (0)
- 1703. Efficacy of Selected Metabolic Inhibitors for the Prevention and Resensitization of High-Level Daptomycin Resistance in Streptococcus mitis-oralis In Vitro and in an Ex Vivo Simulated Endocarditis Model (2022) (0)
- 633. Eravacycline Use in Immunocompromised Patients: Multicenter Evaluation of Clinical and Safety Endpoints (2022) (0)
- Clinical and Economic Comparison of Ceftaroline Fosamil (CPT) and Daptomycin (DAP) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI) (2017) (0)
- Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Dalbavancin Alone and in Combination with Ceftaroline against Methicillin-Resistant Strains (MRSA) of Staphylococcus aureus (2017) (0)
- Potential Theophylline Toxicity with Enoxacin (1986) (0)
- 2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation (2018) (0)
- 1573. Daptomycin Resistant Enterococcus faecium: Combination Therapy Screening (2020) (0)
- FORMULARY FORUM CIPROFLOXACIN (2017) (0)
- Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin (2020) (0)
- 1403. Daptomycin Combined with Low Dose Ceftriaxone Prevents the Emergence of Daptomycin Resistance against Streptococcus mitis-oralis Group in an In vitro Model of Simulated Endocardial Vegetations (SEVs) (2018) (0)
- Table of Contents: Agenda: Title Intersession Reliability of the Emg Amplitude during Incremental Cycle Ergometry: Quadriceps (2013) (0)
- Reply to Scheetz et al. (2022) (0)
- Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (2017) (0)
- Ceftaroline Fosamil (CPT) vs. Vancomycin (VAN) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) (2017) (0)
- Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis-oralis Strains: Target Tissue Clearances and Prevention of Emergence of Daptomycin-Resistance (2023) (0)
- 1295. Activity of SPR206, a Polymyxin B Derivative, Compared to Colistin Alone and in Combination Against Multidrug-Resistant Pseudomonas aeruginosa Strains (2020) (0)
- Race‐Ethnic Differences in B‐Vitamin Biomarkers and Intake Among US Adults in NHANES 2003–2006 (2015) (0)
- Combination Imipenem—Aminoglycoside Therapy (1986) (0)
- Panacea or oversimplification: Relating AUC and troughs. (2022) (0)
- Impact of Ceftolozane–Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Joseph Rybak?
Michael Joseph Rybak is affiliated with the following schools:
